Suspension of trading

Bellicum Pharmaceuticals, Inc. Stock

Stocks

BPXA

US0794814048

Biotechnology & Medical Research

OTC Markets Traded
Delayed Börse Stuttgart 5-day change 1st Jan Change
- EUR -.--% Intraday chart for Bellicum Pharmaceuticals, Inc. -2.31% -53.99%
3 years 0
Extreme 0
0.19
5 years 0
Extreme 0
0.19
10 years 0
Extreme 0
0.19
Manager TitleAgeSince
Chief Executive Officer 66 2024-02-22
Chief Executive Officer 57 2017-01-30
Director TitleAgeSince
Director/Board Member 57 -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap.
23-11-21
Baker Bros. Advisors LP
OptionCompany 4,232,698 44.5721%
23-01-02Fiscal year

Director

80,968 0.9400%
23-01-02Fiscal year

Director

74,739 0.8677%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-2.31% - - 822K
-1.39%-6.15%+56.05%+71.53% 54.49B
+3.13%+11.16%+67.30%+94.35% 55.93B
-0.98%-6.20%+6.26%+428.07% 23.87B
-0.31%-3.70%-18.60%-15.99% 22.86B
+3.51%+7.50%+47.81%-3.33% 20B
+1.94%+0.21%+39.31%-29.41% 17.48B
+10.00%-2.06%+210.10%+370.99% 15.39B
+7.69%+4.38%+56.51%+712.88% 15.19B
+0.17%-0.60%+26.59%+190.64% 14.02B
Average +2.38%+0.07%+54.59%+202.19% 23.92B
Weighted average by Cap. +1.88%+0.47%+52.88%+157.42%

Financials

2021 2022
Net sales 6.2M 5.42M 5.01M 4.63M 8.71M 596M 8.87M 59.73M 23.44M 292M 23.29M 22.77M 1B 1.5M 1.31M 1.21M 1.12M 2.11M 144M 2.15M 14.45M 5.67M 70.55M 5.63M 5.51M 243M
Net income -9.7M -8.48M -7.84M -7.24M -13.64M -932M -13.89M -93.5M -36.68M -456M -36.45M -35.65M -1.57B -24.97M -21.82M -20.17M -18.64M -35.1M -2.4B -35.74M -241M -94.4M -1.17B -93.8M -91.73M -4.04B
Net Debt - -
Logo Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Inc is a United States-based company. The Company operates as a biopharmaceutical company focused on discovering and developing cellular immunotherapies for various forms of cancer.
Employees
13
  1. Stock Market
  2. Stocks
  3. BPXA Stock